Lynn M Bekris1, Debby W Tsuang2,3, Elaine R Peskind2,3, Chang E Yu4,5, Thomas J Montine2,3,6,7, Jing Zhang2,3,6,7, Cyrus P Zabetian4,6,7, James B Leverenz8. 1. Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA. 2. Northwest Network Mental Illness Research, Education and Clinical Center (MIRECC), VA Puget Sound Health Care System, Seattle, Washington, USA. 3. Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, Washington, USA. 4. Geriatric Research, Education, and Clinical Center (GRECC), VA Puget Sound Health Care System, Seattle, Washington, USA. 5. Department of Medicine, University of Washington, Seattle, Washington, USA. 6. Department of Neurology, University of Washington School of Medicine, Seattle, Washington, USA. 7. Northwest Network Parkinson's Disease Research, Education and Clinical Center (PADRECC), VA Puget Sound Health Care System, Seattle, Washington, USA. 8. Lou Ruvo Center for Brain Health, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Abstract
BACKGROUND: Of recent interest is the finding that certain cerebrospinal fluid (CSF) biomarkers traditionally linked to Alzheimer's disease (AD), specifically amyloid beta protein (Aβ), are abnormal in PD CSF. The aim of this exploratory investigation was to determine whether genetic variation within the amyloid precursor protein (APP) processing pathway genes correlates with CSF Aβ42 levels in Parkinson's disease (PD). METHODS: Parkinson's disease (n = 86) and control (n = 161) DNA were genotyped for 19 regulatory region tagging single-nucleotide polymorphisms (SNPs) within nine genes (APP, ADAM10, BACE1, BACE2, PSEN1, PSEN2, PEN2, NCSTN, and APH1B) involved in the cleavage of APP. The SNP genotypes were tested for their association with CSF biomarkers and PD risk while adjusting for age, sex, and APOE ɛ4 status. RESULTS: Significant correlation with CSF Aβ42 levels in PD was observed for two SNPs, (APP rs466448 and APH1B rs2068143). Conversely, significant correlation with CSF Aβ42 levels in controls was observed for three SNPs (APP rs214484, rs2040273, and PSEN1 rs362344). CONCLUSIONS: In addition, results of this exploratory investigation suggest that an APP SNP and an APH1B SNP are marginally associated with PD CSF Aβ42 levels in APOE ɛ4 noncarriers. Further hypotheses generated include that decreased CSF Aβ42 levels are in part driven by genetic variation in APP processing genes. Additional investigation into the relationship between these findings and clinical characteristics of PD, including cognitive impairment, compared with other neurodegenerative diseases, such as AD, are warranted.
BACKGROUND: Of recent interest is the finding that certain cerebrospinal fluid (CSF) biomarkers traditionally linked to Alzheimer's disease (AD), specifically amyloid beta protein (Aβ), are abnormal in PD CSF. The aim of this exploratory investigation was to determine whether genetic variation within the amyloid precursor protein (APP) processing pathway genes correlates with CSF Aβ42 levels in Parkinson's disease (PD). METHODS:Parkinson's disease (n = 86) and control (n = 161) DNA were genotyped for 19 regulatory region tagging single-nucleotide polymorphisms (SNPs) within nine genes (APP, ADAM10, BACE1, BACE2, PSEN1, PSEN2, PEN2, NCSTN, and APH1B) involved in the cleavage of APP. The SNP genotypes were tested for their association with CSF biomarkers and PD risk while adjusting for age, sex, and APOE ɛ4 status. RESULTS: Significant correlation with CSF Aβ42 levels in PD was observed for two SNPs, (APP rs466448 and APH1Brs2068143). Conversely, significant correlation with CSF Aβ42 levels in controls was observed for three SNPs (APP rs214484, rs2040273, and PSEN1rs362344). CONCLUSIONS: In addition, results of this exploratory investigation suggest that an APP SNP and an APH1B SNP are marginally associated with PD CSF Aβ42 levels in APOE ɛ4 noncarriers. Further hypotheses generated include that decreased CSF Aβ42 levels are in part driven by genetic variation in APP processing genes. Additional investigation into the relationship between these findings and clinical characteristics of PD, including cognitive impairment, compared with other neurodegenerative diseases, such as AD, are warranted.
Authors: Michael Ewers; Zhenyu Zhong; Katharina Bürger; Anders Wallin; Kaj Blennow; Stefan J Teipel; Yong Shen; Harald Hampel Journal: Brain Date: 2008-03-11 Impact factor: 13.501
Authors: Trey Sunderland; Gary Linker; Nadeem Mirza; Karen T Putnam; David L Friedman; Lida H Kimmel; Judy Bergeson; Guy J Manetti; Matthew Zimmermann; Brian Tang; John J Bartko; Robert M Cohen Journal: JAMA Date: 2003 Apr 23-30 Impact factor: 56.272
Authors: Jing Zhang; Izabela Sokal; Elaine R Peskind; Joseph F Quinn; Joseph Jankovic; Christopher Kenney; Kathryn A Chung; Steven P Millard; John G Nutt; Thomas J Montine Journal: Am J Clin Pathol Date: 2008-04 Impact factor: 2.493
Authors: Sheu-Fen Lee; Sanjiv Shah; Cong Yu; W Christian Wigley; Harry Li; Myungsil Lim; Kia Pedersen; Weiping Han; Philip Thomas; Johan Lundkvist; Yi-Heng Hao; Gang Yu Journal: J Biol Chem Date: 2003-11-19 Impact factor: 5.157
Authors: Kate R Rosenbloom; Timothy R Dreszer; Michael Pheasant; Galt P Barber; Laurence R Meyer; Andy Pohl; Brian J Raney; Ting Wang; Angie S Hinrichs; Ann S Zweig; Pauline A Fujita; Katrina Learned; Brooke Rhead; Kayla E Smith; Robert M Kuhn; Donna Karolchik; David Haussler; W James Kent Journal: Nucleic Acids Res Date: 2009-11-17 Impact factor: 16.971
Authors: Margarita A Sazonova; Vasily V Sinyov; Anastasia I Ryzhkova; Marina D Sazonova; Tatiana V Kirichenko; Victoria A Khotina; Zukhra B Khasanova; Natalya A Doroschuk; Vasily P Karagodin; Alexander N Orekhov; Igor A Sobenin Journal: Int J Mol Sci Date: 2021-01-12 Impact factor: 5.923
Authors: Hilary Coon; Todd M Darlington; Emily DiBlasi; W Brandon Callor; Elliott Ferris; Alison Fraser; Zhe Yu; Nancy William; Sujan C Das; Sheila E Crowell; Danli Chen; John S Anderson; Michael Klein; Leslie Jerominski; Dale Cannon; Andrey Shabalin; Anna Docherty; Megan Williams; Ken R Smith; Brooks Keeshin; Amanda V Bakian; Erik Christensen; Qingqin S Li; Nicola J Camp; Douglas Gray Journal: Mol Psychiatry Date: 2018-10-23 Impact factor: 15.992